Rejuvenation therapies

Geroprotectors: time to change the way we treat older people?

Ilaria Bellantuono, Professor in Musculoskeletal Ageing, Co-Director, The Healthy Lifespan Institute, Department of Oncology and Metabolism

Removal of senescent cells to extend healthspan & lifespan

Gary Hudson, Executive Chairman, Oisín Biotechnologies

The undeveloped hinterland of rejuvenation

Reason, Co-founder and CEO Repair Biotechnologies & Fight Aging!

Group discussion with various Day 2 speakers

Nina Khera, Co-Founder, Biotein

Supercentenarians – reprogramming cells

Michael D West, Chief Executive Officer, AgeX Therapeutics

From Longevity signatures to Longevity interventions

Vadim Gladyshev, Professor of Medicine and Director, Center for Redox Medicine, Brigham and Women’s Hospital, Harvard Medical School, USA

Anti-aging biotech: past, present and future

Joao Pedro de Magalhaes, Senior Lecturer, University of Liverpool

Rejuvenated stem cells to reverse aging

Bryant Villeponteau, Chairman and Chief Scientific Officer, Centagen, Inc.

‘Rejuvenation therapies’ Ask Me Anything

Various speakers from the conference come together to answer your questions on rejuvenation therapies.

Latest articles

eGenesis’ xenotransplantation trials move closer to in-human

eGenesis' groundbreaking xenotransplantation work with Massachusetts General Hospital to be expanded through additional collaboration. eGenesis has announced it is expanding its research collaboration with the...

New Japanese stem cell clinical trial for aging frailty

Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...

Unlocking the Longevity potential of our oceans

Biologist focuses on the coast of Oman to discover how extreme environments and oceanic life could provide sources for Longevity. With issues like climate change, overfishing...

Alkahest announces phase 2 study treatment of cognitive impairment

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients. Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...